bluebird bio (NASDAQ:BLUE) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of bluebird bio (NASDAQ:BLUE) in a research report report published on Saturday. The firm issued a sell rating on the biotechnology company’s stock.

Other equities analysts also recently issued reports about the stock. Wells Fargo & Company cut their price target on shares of bluebird bio from $3.00 to $2.00 and set an “equal weight” rating on the stock in a report on Wednesday, September 25th. Royal Bank of Canada restated a “sector perform” rating and set a $4.00 price target on shares of bluebird bio in a research note on Thursday, August 15th. Bank of America dropped their price objective on bluebird bio from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th. JPMorgan Chase & Co. downgraded bluebird bio from an “overweight” rating to a “neutral” rating in a research report on Thursday, August 15th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of bluebird bio in a research report on Monday, September 16th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $4.63.

bluebird bio Stock Performance

Shares of BLUE stock opened at $0.46 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.57 and a current ratio of 0.68. The company has a market capitalization of $89.78 million, a price-to-earnings ratio of -0.21 and a beta of 0.76. bluebird bio has a 52-week low of $0.45 and a 52-week high of $5.53. The company has a 50-day simple moving average of $0.52 and a two-hundred day simple moving average of $0.82.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Friday, September 13th. The biotechnology company reported ($0.36) EPS for the quarter. bluebird bio had a negative net margin of 567.29% and a negative return on equity of 207.25%. The business had revenue of $18.57 million for the quarter. Research analysts anticipate that bluebird bio will post -1.41 EPS for the current fiscal year.

Hedge Funds Weigh In On bluebird bio

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in bluebird bio by 19.6% in the 1st quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock worth $13,438,000 after purchasing an additional 1,723,081 shares in the last quarter. AQR Capital Management LLC raised its position in shares of bluebird bio by 315.3% in the second quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock worth $1,223,000 after buying an additional 1,013,144 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in bluebird bio by 19.4% during the second quarter. Bank of New York Mellon Corp now owns 685,757 shares of the biotechnology company’s stock valued at $675,000 after buying an additional 111,574 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in bluebird bio by 38.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 325,111 shares of the biotechnology company’s stock worth $416,000 after buying an additional 90,139 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in bluebird bio by 152.4% in the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 74,185 shares during the last quarter. 87.43% of the stock is currently owned by institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.